Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | |||
Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | ||
Nexavar | Sorafenib | Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) | Do not reimburse | Complete |